As­traZeneca puts $2.5B to­ward first vac­cine fac­to­ry and sec­ond R&D site in Chi­na

As­traZeneca is again boost­ing its man­u­fac­tur­ing foot­print in Chi­na, this time mak­ing a $2.5 bil­lion in­vest­ment to build its first vac­cine plant and sec­ond R …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER